ABBOTT LABORATORIES

Form 3 March 08, 2013

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per response...

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

Statement	3. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]			
03/01/2013			5. If Amendment, Date Original Filed(Month/Day/Year)	
	Director _X_ Officer (give title below	10% = Other w) (specify below	6. Individual or Joint/Group Owner Filing(Check Applicable Line) _X_ Form filed by One Reporting Person	
Table I - N	Non-Derivat	tive Securiti	, ,	
		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)	
60,228		D	Â	
15,300 (1)		I	Profit Sharing Trust	
500 (2)		I	By daughter	
500 (2)		I	By daughter	
pond to the collection of ained in this form are not and unless the form displ	t s	EC 1473 (7-02	2)	
	Table I - I 2. Amount of Beneficially (Instr. 4) 60,228 15,300 (1) 500 (2) ach class of securities beneficially (Instr. 4)	ABBOTT I (Month/Day/Year) 03/01/2013 4. Relationshi Person(s) to I (Check DirectorX Officer (give title below Vice Press Table I - Non-Derivat 2. Amount of Securities Beneficially Owned (Instr. 4) 6. 60,228 2. 15,300 (1) 3. 500 (2) 4. Relationshi Person(s) to I (Check Director Amount of Securities Beneficially Owned (Instr. 4)	(Month/Day/Year) 03/01/2013 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) ——Director ———10% ——X_Officer ——Other (give title below) (specify below Vice President, Controlly	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security	2. Date Exercisable and	3. Title and Amount of	4.	5.	6. Nature of Indirect
(Instr. 4)	Expiration Date	Securities Underlying	Conversion	Ownership	Beneficial

	(Month/Day/Year)		Derivative Security (Instr. 4)		or Exercise Price of	Form of Derivative	Ownership (Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Security: Direct (D) or Indirect (I) (Instr. 5)		
Option (right to buy) (3)	02/18/2006	02/17/2015	Common shares	4,233	\$ 22.267	D	Â	
Option (right to buy) (3)	02/18/2007	02/17/2015	Common shares	4,233	\$ 22.267	D	Â	
Option (right to buy) (3)	02/18/2008	02/17/2015	Common shares	2,076	\$ 22.267	D	Â	
Option (right to buy) (3)	02/17/2007	02/16/2016	Common shares	8,667	\$ 21.2194	D	Â	
Option (right to buy) (3)	02/17/2008	02/16/2016	Common shares	8,666	\$ 21.2194	D	Â	
Option (right to buy) (3)	02/17/2009	02/16/2016	Common shares	8,667	\$ 21.2194	D	Â	
Option (right to buy) (3)	02/16/2008	02/15/2017	Common shares	8,934	\$ 25.2461	D	Â	
Option (right to buy) (3)	02/16/2009	02/15/2017	Common shares	8,933	\$ 25.2461	D	Â	
Option (right to buy) (3)	02/16/2010	02/15/2017	Common shares	8,933	\$ 25.2461	D	Â	
Option (right to buy) (3)	02/15/2009	02/14/2018	Common shares	8,500	\$ 26.6973	D	Â	
Option (right to buy) (3)	02/15/2010	02/14/2018	Common shares	8,500	\$ 26.6973	D	Â	
Option (right to buy) (3)	02/15/2011	02/14/2018	Common shares	8,500	\$ 26.6973	D	Â	
Option (right to buy) (3)	02/20/2010	02/19/2019	Common shares	4,267	\$ 26.015	D	Â	
Option (right to buy) (3)	02/20/2011	02/19/2019	Common shares	4,267	\$ 26.015	D	Â	
Option (right to buy) (3)	02/20/2012	02/19/2019	Common shares	4,266	\$ 26.015	D	Â	
Option (right to buy) (4)	02/19/2011	02/18/2020	Common shares	3,234	\$ 26.1879	D	Â	
Option (right to buy) (4)	02/19/2012	02/18/2020	Common shares	3,233	\$ 26.1879	D	Â	
Option (right to buy) (4)	02/19/2013	02/18/2020	Common shares	3,233	\$ 26.1879	D	Â	

Option (right to buy) (4)	02/18/2012	02/17/2021	Common shares	4,100	\$ 22.3919	D	Â
Option (right to buy) (4)	02/18/2013	02/17/2021	Common shares	4,100	\$ 22.3919	D	Â
Option (right to buy) (4)	02/18/2014	02/17/2021	Common shares	4,100	\$ 22.3919	D	Â
Option (right to buy) (4)	02/17/2013	02/16/2022	Common shares	4,800	\$ 27.0336	D	Â
Option (right to buy) (4)	02/17/2014	02/16/2022	Common shares	4,800	\$ 27.0336	D	Â
Option (right to buy) (4)	02/17/2015	02/16/2022	Common shares	4,800	\$ 27.0336	D	Â
Option (right to buy) (5)	08/02/2013	02/19/2014	Common shares	5,715	\$ 33.88	D	Â
Option (right to buy) (5)	04/27/2013	02/19/2014	Common shares	2,137	\$ 31.6081	D	Â
Option (right to buy) (4)	02/15/2014	02/14/2023	Common shares	21,234	\$ 34.94	D	Â
Option (right to buy) (4)	02/15/2015	02/14/2023	Common shares	21,233	\$ 34.94	D	Â
Option (right to buy) (4)	02/15/2016	02/14/2023	Common shares	21,233	\$ 34.94	D	Â
Option (right to buy) (5)	08/20/2013	02/19/2014	Common shares	1,546	\$ 35.08	D	Â

Reporting Owners

Reporting Owner Name / Address		Kelationships			
	Director	10% Owner	Officer	Othe	
Funck Robert E 100 ABBOTT PARK ROAD ABBOTT PARK, IL 60064	Â	Â	Vice President, Controller	Â	

Signatures

John A. Berry, Attorney-in-Fact for Robert E. Funck

Date

03/08/2013

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2013.

Reporting Owners 3

- (2) The reporting person disclaims beneficial ownership of all securities held by his daughter.
- (3) Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
- (4) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
- (5) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.